mRNA V@kscenes Put You at Risk for Acute Coronary Syndrome by Dr. Joseph Mercola
- Using the PULS cardiac test, researchers have found Pfizer and Moderna mRNA COVID shots dramatically increase biomarkers associated with thrombosis, cardiomyopathy and other vascular events following vaccination
- Pre- and post-injection PULS tests for 566 patients were compared. On average, their PULS scores went from an 11% five-year risk for acute coronary syndrome, to a more than double, 25%, five-year risk
- Those who got the injection for fear that COVID-19 might adversely affect their heart now face the grim reality that they’ve exchanged a potential risk for a more certain one
- Another paper details how the mRNA shot can cause thrombocytopenia (low platelet count) through a mechanism that involves the activation of platelets by antibodies against the spike protein (anti-spike antibodies)
- A mystery that remains to be solved is why only certain people with antibodies to the spike protein (anti-spike antibodies) go on to develop symptoms of platelet activation and thrombocytopenia. One hypothesis is that only a subset of the anti-spike antibodies formed after vaccination can activate platelets and cause thrombocytopenia
In a November 21, 2021, tweet, cardiologist Dr. Aseem Malhotra writes:1
“Extraordinary, disturbing, upsetting. We now have evidence of a plausible biological mechanism of how mRNA vaccine may be contributing to increased cardiac events. The abstract is published in the highest impact cardiology journal so we must take these findings very seriously.”
The abstract he’s talking about is “mRNA COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: A Warning,” published in the November 16, 2021, issue of the journal Circulation.2 (ACS is Acute Coronary Syndrome).
Cardiac Risk Warning
The PULS (Protein Unstable Lesion Signature) cardiac test3 is a simple blood test that detects unstable cardiac lesion rupture, one of the leading causes of heart attacks. As noted by the authors of that paper, this is “a clinically validated measurement of multiple protein biomarkers,” which include:
- IL-16, a proinflammatory cytokine
- Soluble Fas, an inducer of apoptosis
- Hepatocyte growth factor (HGF), a marker for chemotaxis of T-cells into epithelium and cardiac tissue
These and several other proteins are indicative of your immune system’s response to arterial injuries that can result in cardiac lesions. These lesions can become unstable, and if they rupture, they can lead to a heart attack.
So, based on the levels of these biomarkers, the test gives you a score that predicts your 5-year risk, as a percentage chance, of developing acute coronary syndrome (ACS). Elevated levels raise your PULS score while levels below the norm lower it.
COVID-Jabbed Patients More Than Double Their ACS Risk
According to the authors of the Circulation report:4
“The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients. This report summarizes those results.
A total of 566 [patients], aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot.
Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac.
These changes resulted in an increase of the PULS score from 11% 5-year ACS risk to 25% 5-year ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vac.
We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.”
As noted by Malhotra, this is indeed extraordinarily disturbing. Patients who received a two-dose regimen of mRNA more than doubled their five-year ACS risk, driving it from an average of 11% to 25%. Just imagine the shape our medical system and society at large will be in if 1 of every 4 people who got the two-dose regimen ends up with acute heart failure.
Signs and Symptoms to Watch For
ACS is an umbrella term that doesn’t just include heart attacks, but also a range of other conditions involving abruptly reduced blood flow to your heart. Signs and symptoms of ACS typically begin very suddenly, and include:5
|Chest pain/discomfort, often described as aching, pressure, tightness or burning sensations||Pain that radiates from your chest to your shoulders, arms, upper abdomen, back, neck and/or jaw|
|Nausea and/or vomiting||Indigestion|
|Shortness of breath||Sudden heavy sweating|
|Lightheadedness, dizziness and/or fainting||Unusual or inexplicable fatigue|
|Restlessness and/or apprehensiveness|
If you suspect ACS, do not drive yourself to the hospital. Call for an ambulance, as it is a true medical emergency that may need prompt medical attention. Risk factors for ACS have historically included older age, high blood pressure, cigarette smoking, lack of exercise, unhealthy diet, excess body weight and diabetes.
SARS-CoV-2 infection was recently added to that list, but it seems we must also add the COVID jab as well. Those who got the injection for fear that COVID-19 might adversely affect their heart now face the grim reality that they’ve exchanged a potential risk for a more certain one.
In related news, a paper published in the journal Blood Advances reviews “SARS-CoV-2 Spike-Dependent Platelet Activation in COVID-19 Vaccine-Induced Thrombocytopenia.”6 Thrombocytopenia is the medical term for low platelet count.